1.8K Views 2 years ago

Weight Loss Drugs Like Ozempic Can Cause Some Users to Gain Weight

Author Bio

Nicholas Vincent is a passionate environmentalist and freelance writer. He is deeply committed to promoting... Read More

As the United States grapples with rising obesity rates, weight-loss medications such as Ozempic, Wegovy, and Mounjaro have become popular for their potential to significantly reduce body weight. However, emerging reports indicate that about 20% of patients may not experience the anticipated benefits, with some even gaining weight despite continued use.

These medications, known as GLP-1 receptor agonists, function by mimicking a hormone that slows digestion and reduces appetite. In clinical trials, they have shown promising results, with most participants losing between 15% and 22% of their body weight. Yet, real-world experiences suggest a stark variability in individual responses.

Approximately 31 million Americans have tried these drugs at some point, facing the high costs of over $800 per month without insurance. This investment becomes particularly concerning given that many patients may require lifelong treatment to maintain weight loss. Despite this, the Biden administration recently proposed expanding Medicare and Medicaid coverage for these medications, contrasting with skepticism from Donald Trump’s incoming health team.

The non-responsiveness to these drugs has puzzled experts and patients alike. While some, like comedian Tracy Morgan, initially saw a decrease in appetite, they later ‘out-ate’ the drug’s effects, leading to weight gain. This variability highlights the complex nature of obesity, which involves genetics, hormonal influences, and brain-related processes that regulate body weight.

Furthermore, conditions such as polycystic ovarian syndrome (PCOS) and hypothyroidism, which affect millions, can also influence the effectiveness of these treatments. The presence of such underlying conditions complicates the treatment landscape, making it difficult for some to achieve the desired outcomes.

Adding to the complexity are the side effects associated with these medications, including nausea, vomiting, and more severe conditions like gastroparesis—a form of stomach paralysis. These side effects often lead patients to discontinue treatment only to regain weight.

This growing body of evidence suggests that while GLP-1 receptor agonists hold promise, they are not a one-size-fits-all solution and should be considered as part of a broader, personalized approach to obesity treatment.